Shinn-Shing Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shinn-Shing Lee has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Chien-Sheng Wu
Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine Far Eastern Memorial Hospital New Taipei City Taiwan
1 shared publication - Chyou-Shen Lee
Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan
1 shared publication - Hsiao-Yi Lin
Clinical Research Center and Division of Allergy, Immunology and Rheumatology, Department of Medicine, Cheng Hsin General Hospital, Taipei, TWN
1 shared publication - Kun-Hung Chen
Division of Rheumatology and Immunology, Cathay General Hospital, Taipei, Taiwan
1 shared publication - Ping-Ning Hsu
Division of Gastroenterology, Department of Medicine, An Nan Hospital, China Medical University, Tainan, Taiwan
1 shared publication - Toong-Hua Liang
Department of Internal Medicine, Taipei City Hospital Renai Branch, Taipei, Taiwan
1 shared publication
Latest Publications
- Open Access
- 30 June 2020
- Published by AVES YAYINCILIK A.Ş. in Archives of Rheumatology
- Vol. 35 (2) , 170-179
Efficacy and Safety of Opinercept Tumor Necrosis Factor Inhibitor Therapy for Drug-Refractory Rheumatoid Arthritis: A Randomized Clinical Trial
Objectives: This study aims to evaluate the efficacy and safety profile of opinercept for rheumatoid arthritis (RA) patients undergoing disease- modifying anti-rheumatic drugs (DMARDs) therapy. Patients and methods: A total of 98 patients with active RA (17 males, 81 females; mean age 58.6±12.2 years; range, 24.3 to 85.3 years) were randomized into opinercept plus DMARDs (OD group) or placebo plus DMARDs (PD group), in a 24-week treatment period. Primary outcome was American College of Rheumatology score (ACR20) at week 24. Other exploratory endpoints included ACR50, ACR70 and disease activity score-28 (DAS28) at week 12 and 24, tender/swollen joint counts, pain, Health Assessment Questionnaire-Disability Index, erythrocyte sedimentation rate, and C-reactive protein level. Incidence of adverse events (AEs), vital signs and physical findings, and laboratory test results were also evaluated. Results: Patients in OD group showed significantly higher achievement percentage of ACR20 at week 24 than the PD group (76.6% vs. 30.3%, p
- 30 June 2020
- Published by AVES YAYINCILIK A.Ş. in Archives of Rheumatology
- Vol. 35 (2) , 170-179
Open AccessEfficacy and Safety of Opinercept Tumor Necrosis Factor Inhibitor Therapy for Drug-Refractory Rheumatoid Arthritis: A Randomized Clinical Trial
Objectives: This study aims to evaluate the efficacy and safety profile of opinercept for rheumatoid arthritis (RA) patients undergoing disease- modifying anti-rheumatic drugs (DMARDs) therapy. Patients and methods: A total of 98 patients with active RA (17 males, 81 females; mean age 58.6±12.2 years; range, 24.3 to 85.3 years) were randomized into opinercept plus DMARDs (OD group) or placebo plus DMARDs (PD group), in a 24-week treatment period. Primary outcome was American College of Rheumatology score (ACR20) at week 24. Other exploratory endpoints included ACR50, ACR70 and disease activity score-28 (DAS28) at week 12 and 24, tender/swollen joint counts, pain, Health Assessment Questionnaire-Disability Index, erythrocyte sedimentation rate, and C-reactive protein level. Incidence of adverse events (AEs), vital signs and physical findings, and laboratory test results were also evaluated. Results: Patients in OD group showed significantly higher achievement percentage of ACR20 at week 24 than the PD group (76.6% vs. 30.3%, p